艾可藍(300816.SZ):擬使用不超6億元閒置募集資金及自有資金購買理財產品
格隆匯 2 月 23日丨艾可藍(300816.SZ)公佈,公司於2021年2月23日召開第二屆董事會第十七次會議及第二屆監事會第十四次會議,審議通過了《關於使用部分閒置募集資金及自有資金購買理財產品的議案》,同意公司在確保募投項目正常進行、公司正常生產經營及資金安全的情況下,使用不超過人民幣6億元閒置募集資金及自有資金購買理財產品,其中擬使用不超過人民幣2億元的閒置募集資金購買安全性高、流動性好、期限不超過12個月的理財產品,擬使用不超過人民幣4億元的閒置自有資金購買中低風險的理財產品。
在上述額度內,資金可滾動使用,授權有效期為股東大會審議通過本議案之日起一年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.